Quarterly Report · 10-Q

Aura Biosciences, Inc.

AURANASDAQEQUITYCurrent

Quarterly Report

Filed Aug 11, 2026Accepted Aug 11, 2026, 7:15 AM EDTCIK 1501796Accession 0001193125-26-343429

Company context

Aura Biosciences is a clinical-stage biotechnology company developing bel-sar, a potentially transformative, first-in-class therapy for patients living with ocular cancers. Bel-sar represents an entirely novel approach to treating ocular cancers via its dual mechanisms of action of acute tumor necrosis and secondary anti-tumor immune activation. The Phase 3 registration study of Bel-sar in early choroidal melanoma, the largest patient segment of uveal melanoma, is fully enrolled, and earlier stage studies in metastases to the choroid and cancers of the ocular surface are ongoing. Aura's mission is to improve outcomes for patients living with ocular cancers by delivering a therapy that not only arrests tumor growth but also preserves vision and quality of life.

Current securities

AURANASDAQ · EQUITY · Current

Recent company filings

Registered securities in this filing

AURA BIOSCIENCES, INC. · 10-Q · Filed 2026-08-11

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock, par value $0.00001 per share

Symbol: AURA
Exchange: NASDAQ
Classification: COMMON
Status: Current

Filing context

Context: C_8363780b-fc06-4426-9e5b-a0ac1cdce515

Dimensions: Not supplied

Accession 000119312526343429 · 1 registered-security cover member

Read the exact SEC filing ↗

As-filed source

Primary evidence

As filedOpen full document ↗

Get the free weekly BCS email.